Strategic leadership DiNAQOR is strengthening its leadership with hires for CEO and Chief Scientific Officer in December 2025, signaling a strategic push to accelerate partnerships and commercial success in advanced therapies—an opportunity to engage in high-level alliance discussions and co-development opportunities.

Manufacturing moat With the launch of DiNAQOR DiNAMIQS, a dedicated biomanufacturing subsidiary, the company positions itself to accelerate development timelines and reduce costs and risk for genetic medicines, opening doors for collaborations on scalable GMP manufacturing, process development, and tech transfer.

Cardiac focus DiNAQOR specializes in cardiac gene therapy, including engineered heart tissue technology and cardiac-specific capsids, creating a targeted value proposition for biotech and pharma partners seeking to address inherited cardiac diseases and organ-targeted gene delivery.

Global footprint Having a presence in Switzerland, the US, and Germany enables cross-border collaborations, access to European and North American funding ecosystems, and multi-region clinical development opportunities—ideal for strategic partnerships and regional manufacturing deals.

Early-stage to clinic As a platform for early-stage drug development and manufacturing, DiNAQOR offers partnership avenues across discovery to early clinical development, including access to proprietary EHT and LRP technologies, which can be attractive for early-stage gene therapy programs seeking speed and novelty.